February 19, Dear Ms. Leonhart:

Size: px
Start display at page:

Download "February 19, 2013. Dear Ms. Leonhart:"

Transcription

1 Ms. Michele M. Leonhart Administrator Drug Enforcement Administration U.S. Department of Justice 8701 Morrissette Drive Springfield, VA Re: Notice of proposed rulemaking on Disposal of Controlled Substances, pursuant to Federal Register notice published Dec, 21, 2012, Vol. 77 No. 246, Docket No. DEA-316. Dear Ms. Leonhart: On behalf of our more than 2,000 members, the Association for the Healthcare Environment (AHE), a personal membership group of the American Hospital Association appreciates the opportunity to comment on the Drug Enforcement Administration s (DEA) proposed rule implementing the Secure and Responsible Drug Disposal Act of AHE is the leader in environmental services education and training related to cleaning and surface disinfection and management of the waste streams generated during the course of medical care. AHE also provides recommended practice training on providing a clean, safe and quality care environment for patients, staff and visitors. We appreciate the time and effort DEA has invested in drafting the proposed regulation that expands available options for the collection of controlled substances from ultimate users for purposes of disposal. We also appreciate DEA s efforts to address the continuing concerns regarding disposal of controlled substances within the health care community. Our letter provides comments on the various health care sectors impacted by the changes in the proposed rule. To that effect, AHE has divided our comments into two sections, mirroring the approach taken by DEA in the proposed rule. The first section offers comments specific to the health care sector that would be impacted by the provisions in the proposed regulation. The second section offers comments and suggestions on the definitions contained in the proposed rule.

2 Page 2 of 8 IMPACT ON CERTAIN HEALTH CARE SECTORS LONG TERM CARE FACILITIES (LTCF) The Disposal Act authorized the U.S. Attorney General to develop regulations to permit LTCFs to dispose of controlled substances on behalf of ultimate users who reside or have resided at such facilities in a manner that provides effective controls against diversion and is consistent with public health and safety. As such, DEA proposes to allow collection receptacles to be placed at LTCFs for the disposal of controlled substances in accordance with outlined requirements. In the proposed regulation, DEA states that access to the inner liner is restricted to authorized employees of the registered retail pharmacy, and that no employees of the LTCF will have access to or influence over the contents of the collection receptacle. We are concerned about this provision because the collection receptacles may be full between medication delivery times or when the retail pharmacy is closed. We recommend that appropriate LTCF personnel (a nursing director or assistant director) should be able to remove, store and replace the liners when necessary. It also may be appropriate to permit only controlled substances in the collection receptacles. In addition, non-controlled substances should not be transferred to the retail pharmacy for secure storage and subsequently transported for disposal. LTCF personnel should be sorting the noncontrolled substances into the appropriate pharmaceutical waste receptacles for storage and disposal, consistent with current Environmental Protection Agency (EPA) requirements. Currently, only one LTCF employee delivers controlled substances. We recommend actively soliciting comments from LTCFs and organizations representing them to learn more about financial feasibility of using authorized retail pharmacy employees to pick up the liners. Comingling Substances. DEA proposes that LTCFs be permitted to dispose of controlled substances in Schedules II through V on behalf of an ultimate user who resides or has resided at the LTCF and that controlled and non-controlled substances may be comingled in the collection receptacle. Comingling increases costs; receptacles fill more quickly; and non-controlled substances may be classified as hazardous waste by EPA definition. Commingling of controlled and non-controlled substances will be problematic in states that consider senior facilities (LTCF in this instance) to be a business. All waste stream generation in such businesses are subject to EPA s Resource Conservation and Recovery Act (RCRA) hazardous waste regulations. The transfer of any pharmaceutical waste meeting the definition of hazardous would be in violation of RCRA regulations for the LTCF and the waste hauler. Waste separation enables the facility to maintain regulatory compliance within RCRA.

3 Page 3 of 8 HOSPITALS AND OTHER HEALTH CARE FACILITIES In the proposed rule, DEA states that a controlled substance dispensed for immediate administration pursuant to an order for medication in an institutional setting remains in the possession of that registered institution even if the substance is not fully exhausted. We urge DEA to clarify the status of used fentanyl and testosterone patches. While there will be drug remaining in the used patch, the amount is unknown and variable. Storage of these patches, which are used from DEA s perspective and out of the hospital s inventory, is impractical and could lead to additional diversion. Typically, hospitals dispose of these in the red sharps containers. Hospice facilities and LTCFs share similar challenges. Disposal of Controlled Substances by Registrants. DEA proposes to allow non-practitioners to deliver (i.e., transfer) controlled substances themselves for the purpose of disposal provided that such substances are transported directly to the destruction location and accompanied by two authorized employees. We are concerned because the destruction facility may be located hundreds or thousands of miles from the non-practitioner. Currently, some reverse distributors have received permission from the DEA Special Agent in Charge (SAC) to send the controlled substances via common carrier with witnessed inventories, both upon departure and upon receipt at the destruction facility. The SAC s also have authorized the hiring of off-duty law enforcement officers or other security personnel to witness the receipt, unloading and actual destruction by incineration of the controlled substances. The contracted security personnel then sign Form 41. Due to insurance regulations and operational policy, common carriers (whether a national or local carrier) do not normally allow employees of other companies to ride in their vehicle, and many reverse distributors do not operate their own trucking fleets. Authorized Employees. DEA proposes that an authorized employee is a person directly employed by the registrant full time. We believe this definition is problematic, specifically with respect to pharmacists and nurses, both of whom may be part-time employees. In some pharmacy departments, pharmacy staff may be employees of an outside contractor or consulting firm. With respect to nurses, many are part-time or may be contract labor from a nursing pool. We urge DEA to change the language to encompass both of these situations and define an authorized employee as someone who has been hired or contracted to perform the duties normally performed by a full-time employee of the registrant and who is duly licensed to do so. Record Requirements. DEA proposes that a registrant that destroys controlled substances or causes the destruction of controlled substances is required to maintain a record of the destruction in a form to be issued by DEA. This form will be DEA Form 41. The requirement to use a paper Form 41, especially in hospitals where automated/electronic reporting dispensing machines or automated dispensing cabinets are in use for documentation of controlled substances by two health care professionals as witnesses, is burdensome to clinicians who already have a tremendous amount of paperwork. The standard data captured by the aforementioned equipment includes the patient s name for whom the dose was removed from the machine; the name and strength of the drug; the amount of controlled substance administered; the amount of controlled

4 Page 4 of 8 substance wasted, ; the means of wasting (device, flushing, or returned to pharmacy for additional management); and the identity of the two health care professionals who witnessed the wasting. Additionally, some equipment can be programmed to provide prompts to the administering nurse/clinician if the wasting process is not completed and can send notifications to nursing supervisors or to the pharmacy department of any unresolved wasting discrepancies. These records are readily available for at least two years and are archived indefinitely. The records are exportable into Microsoft Excel and can also be customized through a report writer function. Returning to a paper Form 41 would not only be burdensome and take away time from bedside care, it may provide decreased functionality with respect to identifying diversion. In a large hospital, it is not unusual for 10,000 doses of controlled substances to be delivered daily, illustrating the difficulties of a manual system. We encourage DEA to seek additional information, and perhaps alternative language from the major manufacturers of automated dispensing machines. Methods of Destruction. DEA proposes a standard of destruction non-retrievable for persons that intend to destroy controlled substances. DEA is not requiring a particular method of destruction, so long as the desired result is achieved. While this statement is well-intentioned, DEA does not specify what it considers to be a non-retrievable substance. For example, do the new and available technologies such as the sequestering of left-over drug in fentanyl patches and/or the new sequestering sink system constitute acceptable methods of rending nonretrievable? Definition of Non-retrievable. DEA states that the proposed definition of non-retrievable means to permanently alter any controlled substance s physical and/or chemical state through irreversible means in order to render that controlled substance unavailable and unusable for all practical purposes. Incineration is not practical in most facilities for small amounts. LTCFs will require a grace period for the retail pharmacy provider market to install collectors. We recommend DEA authorize destruction methods as a means to remove the uncertainty as to what methods are acceptable. This uncertainty also prevents exploration and discovery of solutions that could provide mutual benefit to DEA and health care facilities. To illustrate the need for clarity, once the controlled substances are rendered non-retrievable at the health care facility by methods acceptable to DEA, is it permissible that they be transported and/or shipped as solid waste without additional documentation or monitoring with respect to the Department of Transportation s Motor Carrier Safety Assistance Program requirements? Again, we urge DEA to clarify its response what it considers to be a non-retrievable substance. In the absence of regulatory comment on new technologies, the non-specific language potentially inhibits development of innovative solution sets. In the proposed rule, DEA states that flushing does not render the drugs non-retrievable. While not an environmentally friendly option, from a practical perspective and by DEA definition, said substances could be considered non-retrievable through flushing. In many settings, including LTCFs and in smaller practices including physician, veterinary and dental, flushing may be the only option in the short term in order to maintain compliance with the regulations and to prevent diversion. However, until DEA

5 Page 5 of 8 renders guidance on additional methods for rendering controlled substances non-retrievable and the market provides cost-effective alternatives, flushing must remain an option. In the meantime, the industry could continue working on options for DEA review. Clarity of Reporting Requirements. DEA also proposes that the authorized registrant report all recalled controlled substance acquisition transactions pursuant to 21 CFR Such registrants may report either each individual receipt or a single transaction that includes all recalled controlled substances of the same name and finished form (e.g., all 10-milligram tablets or all 5-milligram concentration per fluid ounce or milliliter) received from ultimate users. It is unclear if registrants must report to DEA or if reporting to the Food and Drug Administration (FDA) is sufficient. It is our recommendation that single reporting be acceptable due to time consuming and duplicative paperwork. DEA estimates there will be 68,344 respondents (Distributors 828, Reverse Distributors 60, Manufacturers 522, Retail Pharmacies 66,934) to this information collection. The number of respondents (68,344) represents the total number of registrants in business activities that are most likely to destroy controlled substances. DEA does not list hospitals, surgery centers, physician offices, dentists or veterinarians as potential registrants that will routinely dispose of controlled substances and required to use Form 41. The concerns expressed above may apply beyond the hospital setting as automated dispensing machines become more prevalent in alternate care markets. COMMENTS ON DEFINITIONS IN PROPOSED RULE Below we offer comments on definitions contained in the proposed rule as well as language suggestions we would like to be included in future rulemaking. DISPOSALS OF CONTROLLED SUBSTANCES BY REGISTRANTS Registrant disposal. In the proposed rule s section on disposal of controlled substances by registrants, DEA says that in the event that a practitioner is required regularly to dispose of controlled substances, the Special Agent in Charge may authorize the practitioner to dispose of such substances, in accordance with subparagraph (a)(2) of this section, without prior application in each instance, on the condition that the practitioner keep records of such disposal and files periodic reports with the SAC summarizing the disposals. NOTE: Subparagraph (a)(2) Promptly deliver that controlled substance to a reverse distributor s registered location by common or contract carrier or by reverse distributor pick-up at the registrant s registered location. This language does not define practitioner and seems to indicate a blanket authorization to destroy requires the use of reverse distributors. This is not practical for the following reasons. The language limits routine destruction by nurses, pharmacists, dentists, veterinarians, etc. to reverse distributors. Only retail and hospital pharmacies currently use reverse distributors, and then primarily for outdated, unused stock. It is not economically viable for others to do so. In

6 Page 6 of 8 addition, small amounts of controlled substances, such as those left over in a vial, syringe, or IV bag, are not conducive to collecting, inventorying and shipping. These should be destroyed onsite, either by flushing or by an alternative method as described by DEA. If the restriction to using reverse distributors was not the intent of the regulations, the language should be modified to remove any ambiguity. DISPOSAL OF CONTROLLED SUBSTANCES BY ULTIMATE USERS AND OTHER NON- REGISTRANTS Authorization to Collect from Non-registrants. DEA says the following non-registrant persons in lawful possession of a controlled substance in Schedules II, III, IV or V may transfer that substance to the authorized persons listed in paragraph (a) of this section, and in a manner authorized by this part, for the purpose of disposal: (2) Any person lawfully entitled to dispose of a decedent s property if that decent was an ultimate user that died while in lawful possession of a controlled substance. We believe this definition should be expanded to include any parent or guardian of a minor in lawful possession of a controlled substance, and any person lawfully entitled to dispose of property for a person incapacitated and unable to dispose of their lawfully obtained controlled substance. Registrants Authorized to Collect and Authorized Collection Activities. DEA states authorized collectors may receive mail-back packages at a registered location that has an on-site method of destruction. This requirement would restrict the mail-back option to the few reverse distributors that have incinerators. Given the amount of recordkeeping required of reverse distributors, we see no reason why reverse distributors should not be able to participate in mail-back programs, just as they participate in recall and return efforts. Collector Inventory, Recordkeeping, Reporting and Order Form Requirements. DEA says for registrants authorized to collect through a mail-back program, the record shall include the following: (ii) For those unused packages provided to a third party to make available to ultimate users and other authorized non-registrants the name of the third party and physical address of the location receiving the unused packages, date sent, and the number of unused packages sent with the corresponding unique identification numbers. We are unclear if the numbers on the packages need to be reconciled with the initial inventory and if there is a time limit on the viability of the packaging. Registered Reverse Distributor and Distributor Acquisition of Controlled Substances from Law Enforcement Agencies or Authorized Collectors. DEA states that a registered reverse distributor or registered distributor that acquires controlled substances must destroy, or cause the controlled substances to be destroyed, as soon as practicable but no longer than fourteen calendar days of receipt.

7 Page 7 of 8 We believe this should be changed to 60 calendar days of receipt. Fourteen days does not allow enough time. Take-back Events. DEA states that each take-back event should have at least one receptacle for the collection of permitted substances. We are concerned that this will allow controlled substances to be mixed with other drugs. Using the same receptacle that is required in a retail pharmacy, etc. is not operationally practical. In addition, DEA says only ultimate users and persons entitled to dispose of an ultimate user decedent s property in lawful possession of a controlled substances in Schedule II, III, IV or V may transfer such substances to the law enforcement agency during the take-back event. No other person may handle the controlled substances at any time. We are concerned that this would eliminate the option of having pharmacists on hand to sort the controlled substances from non-controlled substances. Not only would this cause collection bins to reach capacity too quickly, it would require law enforcement to take possession of all discarded drugs, rather than the waste vendor, who could immediately transport the noncontrolled substances to an appropriate incinerator. Many law enforcement agencies would not have the facilities to store the drugs until they can be shipped to a reverse distributor or others. Collection Receptacles. DEA says for authorized collectors, a controlled substance collection receptacle shall meet design specifications, including having the outer container prominently display a sign indicating that only non-controlled drugs and Schedule II, III, IV, or V controlled substances are acceptable. The general public does not understand this language. A suggested alternative could be to include the following language in some form: ONLY prescription and over-the-counter drugs can be accepted in this container. No illegal drugs. No syringes/needles, no cosmetics, toothpaste, deodorant or other personal care materials. Ultimate user delivery and Automated Reports and Consolidated Orders System (ARCOS). We are unclear about what code a registrant should use to designate the entity from which the registrant received the recalled controlled substance. Since this information is already being captured for the FDA under a recall, what additional value does ARCOS reporting offer? Also, does it apply only to Schedule II drugs and Schedule III narcotics? Destruction Procedures. DEA says if the controlled substances are transferred to a person registered under the Act and authorized to accept the controlled substances for purposes of disposal, two authorized employees of the transferring registrant shall load and unload or observe the loading and unloading of any controlled substances until transfer is complete. This is problematic because the site of destruction may be thousands of miles away and shipments must be made frequently (30 days is the shortest amount of time recommended by

8 Page 8 of 8 DEA). It is cost prohibitive to fly employees to and from destruction sites this often. The receiving registrant should be responsible for documenting the accurate receipt of the transferred controlled substances as is now the case for all forward-bound controlled substances. There should be no need for the transferring registrant to have employees present for the unloading. In addition, DEA says if the controlled substances are transported by a registrant to the location of destruction, the following procedures shall be followed: Two authorized employees of the transporting registrant shall accompany the controlled substances to the destruction location; two authorized employees of the transporting registrant shall load and unload or observe the loading and unloading of the controlled substances; two authorized employees of the transporting registrant shall handle or observe the handling of any controlled substance until the substance is rendered non- retrievable; and two authorized employees of the transporting registrant shall personally witness the destruction of the controlled substances until it is rendered non-retrievable. As we noted above, the site of destruction may be thousands of miles away. The registrant would need to use a common carrier, or in the case of a RCRA hazardous waste, a hazardous waste transporter, neither of whom will allow a non-employee to accompany them. It also is cost prohibitive to fly employees to and from destruction sites this often. We recommend DEA continue to enable the hiring of responsible contractors, such as off-duty law enforcement personnel, at the site of the destruction facility to witness the unloading and destruction of the controlled substances. We further recommend DEA examine the successful practices that have been in use for the past 20 years to determine if any significant diversion has occurred and, assuming they have worked effectively, continue to utilize them. Recordkeeping Requirements. DEA states that in addition to any other recordkeeping requirements, any registered person that destroys or causes the destruction of a controlled substance shall maintain a record of destruction on a form issued by DEA. As we noted earlier in our letter, a revised DEA Form 41 will not work as well as the automated systems that are currently in use at hospitals and some other medical facilities. We urge DEA to enable the use of the current electronic reporting systems used by nurses in the automated dispensing machines, which are much more effective at identifying potential diversion. Thank you again for the opportunity to comment on this important proposed regulation. Should you have concerns or questions, please contact me at pcostello@aha.org or (312) Sincerely, /s/ Patti Costello Executive Director Association for the Healthcare Environment

Title 16. Board of Pharmacy Proposed Text

Title 16. Board of Pharmacy Proposed Text Title 16. Board of Pharmacy Proposed Text Proposal to add new Article 9.1 of Division 17 of Title 16 of the California Code of Regulations and a new Article title as follows: Article 9.1. Prescription

More information

Disposal of Pharmaceuticals, and their empty containers, in the Workplace

Disposal of Pharmaceuticals, and their empty containers, in the Workplace Disposal of Pharmaceuticals, and their empty containers, in the Workplace Prepared by Bio-Team Mobile LLC There is a lot of misinformation being circulated about disposal of pharmaceuticals ever since

More information

Statement of Mary L. Hendrickson,PharmD,MBA,RAC Director of Quality & Regulatory Affairs Capital Returns Inc., d/b/a Genco Pharmaceutical Services

Statement of Mary L. Hendrickson,PharmD,MBA,RAC Director of Quality & Regulatory Affairs Capital Returns Inc., d/b/a Genco Pharmaceutical Services Statement of Mary L. Hendrickson,PharmD,MBA,RAC Director of Quality & Regulatory Affairs Capital Returns Inc., d/b/a Genco Pharmaceutical Services Before The Special Committee on Aging United States Senate

More information

Controlled Substance Policy and Procedures NORTHERN ILLINOIS UNIVERSITY OFFICE OF RESEARCH COMPLIANCE AND INTEGRITY

Controlled Substance Policy and Procedures NORTHERN ILLINOIS UNIVERSITY OFFICE OF RESEARCH COMPLIANCE AND INTEGRITY 2015 Controlled Substance Policy and Procedures NORTHERN ILLINOIS UNIVERSITY OFFICE OF RESEARCH COMPLIANCE AND INTEGRITY Contents A. Controlled Substance Policy... 4 1. Background, Purpose, and Scope...

More information

EPA s proposed hazardous waste pharmaceutical regulations

EPA s proposed hazardous waste pharmaceutical regulations EPA s proposed hazardous waste pharmaceutical regulations November 4, 2015 By J. Timothy Ramsey The United States Environmental Protection Agency ( EPA ) published proposed regulations in the Federal Register

More information

EPA Comments on the Development of Safe and Effective Drug Collection and Disposal Methods

EPA Comments on the Development of Safe and Effective Drug Collection and Disposal Methods EPA Comments on the Development of Safe and Effective Drug Collection and Disposal Methods Robert W. Dellinger, Division Director Materials Recovery and Waste Management Division Office of Resource Conservation

More information

DISPOSAL OF CONTROLLED SUBSTANCES

DISPOSAL OF CONTROLLED SUBSTANCES DISPOSAL OF CONTROLLED SUBSTANCES WELCOME Kate Gainer, PharmD Executive Vice President and CEO Iowa Pharmacy Association Outline of Today s 2/2/2 PRESENTER Jan Harris Director, EHS Customer Compliance

More information

The Future of Pharmaceutical Waste Regulation. Elise Paeffgen Senior Associate Alston & Bird LLP

The Future of Pharmaceutical Waste Regulation. Elise Paeffgen Senior Associate Alston & Bird LLP The Future of Pharmaceutical Waste Regulation Elise Paeffgen Senior Associate Alston & Bird LLP Issue/Problem Pharmaceuticals in municipal drinking water Sources: Human ingestion/excretion Flushed pharmaceutical

More information

American Society of Consultant Pharmacists Background

American Society of Consultant Pharmacists Background American Society of Consultant Pharmacists 1321 Duke St. Alexandria, VA 22314-3563 Phone: 703-739-1300 FAX: 703-739-1321 E-mail: info@ascp.com www.ascp.com March 4, 2009 RCRA Docket Environmental Protection

More information

USE OF CONTROLLED SUBSTANCES AN OVERVIEW FOR RESEARCHERS

USE OF CONTROLLED SUBSTANCES AN OVERVIEW FOR RESEARCHERS USE OF CONTROLLED SUBSTANCES AN OVERVIEW FOR RESEARCHERS APPLICABILITY (WITH REGARD TO CONTROLLED SUBSTANCES) This presentation is applicable to: Animal and non-animal research This presentation is mostly

More information

Reverse Distribution: An Intersection of Regulations Charlotte A. Smith, Senior Regulatory Advisor, PharmEcology Services, WM National Services, Inc.

Reverse Distribution: An Intersection of Regulations Charlotte A. Smith, Senior Regulatory Advisor, PharmEcology Services, WM National Services, Inc. Reverse Distribution: An Intersection of Regulations Charlotte A. Smith, Senior Regulatory Advisor, PharmEcology Services, WM National Services, Inc. Legal Disclaimer This course is solely for educational

More information

DEPARTMENT OF LICENSING AND REGULATORY AFFAIRS DIRECTOR S OFFICE PHARMACY PROGRAM FOR UTILIZATION OF UNUSED PRESCRIPTION DRUGS

DEPARTMENT OF LICENSING AND REGULATORY AFFAIRS DIRECTOR S OFFICE PHARMACY PROGRAM FOR UTILIZATION OF UNUSED PRESCRIPTION DRUGS DEPARTMENT OF LICENSING AND REGULATORY AFFAIRS DIRECTOR S OFFICE PHARMACY PROGRAM FOR UTILIZATION OF UNUSED PRESCRIPTION DRUGS (By authority conferred on the director of the department of licensing and

More information

Managing Pharmaceutical Waste at the LTC Provider Pharmacy

Managing Pharmaceutical Waste at the LTC Provider Pharmacy Managing Pharmaceutical at the LTC Provider Pharmacy Is your pharmacy compliant with all regulations related to pharmaceutical waste? The long-term care (LTC) industry is currently faced with the simultaneous

More information

PHARMACEUTICAL WASTE UPDATE ON HANDLING AND DISPOSAL ASTSWMO MEETING August 11, 2011

PHARMACEUTICAL WASTE UPDATE ON HANDLING AND DISPOSAL ASTSWMO MEETING August 11, 2011 PHARMACEUTICAL WASTE UPDATE ON HANDLING AND DISPOSAL ASTSWMO MEETING August 11, 2011 Pharmaceutical Waste Getting the attention it deserves Are there Federal, State and Local laws & regulations to comply

More information

Pursuant to the authority vested in the Commissioner of Health by Article 33 of the

Pursuant to the authority vested in the Commissioner of Health by Article 33 of the Electronic Prescriptions and Records for Hypodermic Needles and Hypodermic Syringes Effective date: 10/9/13 Pursuant to the authority vested in the Commissioner of Health by Article 33 of the Public Health

More information

Hazardous Waste Pharmaceuticals Proposed Rule

Hazardous Waste Pharmaceuticals Proposed Rule Hazardous Waste Pharmaceuticals Proposed Rule Note that this presentation is an overview of the major provisions of the proposed rule and is not a comprehensive look at every provision of the proposed

More information

Iowa School Medication Waste Guidance

Iowa School Medication Waste Guidance Iowa School Medication Waste Guidance Medication Waste Guidance Medication administration in the school setting is a component of the nursing practice. The Iowa Board of Nursing acts in collaboration with

More information

Definitions: The Certification of Exemption memorandum must be signed by the principal investigator s dean or department chair.

Definitions: The Certification of Exemption memorandum must be signed by the principal investigator s dean or department chair. University of Pittsburgh Guidelines for the Ordering and Use of Prescription Drugs and Devices and Controlled Substances for Non- Clinical Laboratory Research Definitions: 1. Authorized Agent(s) of the

More information

CHAPTER 61-03-02 CONSULTING PHARMACIST REGULATIONS FOR LONG-TERM CARE FACILITIES (SKILLED, INTERMEDIATE, AND BASIC CARE)

CHAPTER 61-03-02 CONSULTING PHARMACIST REGULATIONS FOR LONG-TERM CARE FACILITIES (SKILLED, INTERMEDIATE, AND BASIC CARE) CHAPTER 61-03-02 CONSULTING PHARMACIST REGULATIONS FOR LONG-TERM CARE FACILITIES (SKILLED, INTERMEDIATE, AND BASIC CARE) Section 61-03-02-01 Definitions 61-03-02-02 Absence of Provider or Consulting Pharmacist

More information

Resource Directory for the Management of Pharmaceuticals in King County

Resource Directory for the Management of Pharmaceuticals in King County Resource Directory for the Management of Pharmaceuticals in King County Interagency Regulatory Analysis Committee (IRAC) and Local Hazardous Waste Management Program in King County October 2003 SQG-PHARM-1(10/03)

More information

EPA s Proposed Rule Regulating Pharmaceuticals Under RCRA

EPA s Proposed Rule Regulating Pharmaceuticals Under RCRA EPA s Proposed Rule Regulating Pharmaceuticals Under RCRA September 3, 2015 Environmental EPA proposed a rule to regulate hazardous waste pharmaceuticals which include a number of FDA-approved drugs under

More information

PHARMACEUTICAL WASTE MANAGEMENT DUKE UNIVERSITY HEALTH SYSTEM

PHARMACEUTICAL WASTE MANAGEMENT DUKE UNIVERSITY HEALTH SYSTEM PHARMACEUTICAL WASTE MANAGEMENT DUKE UNIVERSITY HEALTH SYSTEM BLUE BIN DRUGS ONLY NO EMPTY Packages, NO Gloves NO Scissors, Syringes, Needles, IVs Scalpels, Forceps BLUE BIN PROGRAM PURPOSE AND OBJECTIVE:

More information

U.S. Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation and Research (CDER) March 2006 Compliance

U.S. Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation and Research (CDER) March 2006 Compliance Guidance for Industry Prescription Drug Marketing Act Donation of Prescription Drug Samples to Free Clinics U.S. Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation

More information

CRITERIA AND PROCEDURES FOR MODEL HOME-GENERATED PHARMACEUTICAL WASTE COLLECTION AND DISPOSAL PROGRAMS

CRITERIA AND PROCEDURES FOR MODEL HOME-GENERATED PHARMACEUTICAL WASTE COLLECTION AND DISPOSAL PROGRAMS CRITERIA AND PROCEDURES FOR MODEL HOME-GENERATED PHARMACEUTICAL WASTE COLLECTION AND DISPOSAL PROGRAMS (ADOPTED BY THE CALIFORNIA INTEGRATED WASTE MANAGEMENT BOARD ON FEBRUARY 24, 2009) CIWMB s Objectives

More information

- - - β a The Tox 21 programme is pooling federal resources to use robotics technology to screen thousands of chemicals for potential toxicity, using screening data to predict the potential toxicity of

More information

UTCVM PHARMACY STANDARD OPERATING PROCEDURES

UTCVM PHARMACY STANDARD OPERATING PROCEDURES UTCVM PHARMACY STANDARD OPERATING PROCEDURES Updated: 4/5/2004 I. General Procedures A. Hours: The Pharmacy will be open Monday through Friday, 8:00AM to 6:00PM; Saturday 8:00AM to 1:00PM. The Pharmacy

More information

ARKANSAS PRODUCTS: PRODUCT EXEMPTIONS: SALES LIMITS: SALES RESTRICTIONS:

ARKANSAS PRODUCTS: PRODUCT EXEMPTIONS: SALES LIMITS: SALES RESTRICTIONS: ARKANSAS PRODUCTS: Any product containing ephedrine, pseudoephedrine, or phenylpropanolamine or any of their salts, isomers, or salts of isomers, alone or in a mixture. (A.C.A. 5-64-212) PRODUCT EXEMPTIONS:

More information

Conflicts of Interest. Disposal of Pharmaceutical Waste: What a Technician. Who is interested in proper pharmaceutical waste disposal?

Conflicts of Interest. Disposal of Pharmaceutical Waste: What a Technician. Who is interested in proper pharmaceutical waste disposal? Conflicts of Interest Disposal of Pharmaceutical Waste: What a Technician Should Know Presented by Michael McEvoy Pharm.D. NorthShore University HealthSystem The speaker has nothing to disclose in relation

More information

Washington State Environmental Regulations and Pharmaceutical Waste

Washington State Environmental Regulations and Pharmaceutical Waste Washington State Environmental Regulations and Pharmaceutical Waste Kimberly Goetz Hazardous Waste and Toxics Reduction Program Washington State Department of Ecology October 5, 2015 Same Waste, Sometimes

More information

ARKANSAS. Downloaded January 2011

ARKANSAS. Downloaded January 2011 ARKANSAS Downloaded January 2011 302 GENERAL ADMINISTRATION 302.11 Pharmacies operated in nursing homes shall be operated in compliance with Arkansas laws and shall be subject to inspection by personnel

More information

Controlled Substance Policy for Research

Controlled Substance Policy for Research Controlled Substance Policy for Research The University of North Carolina at Greensboro Approved 7/1/2013 I. Purpose University researchers may, in the course of lawful research, teaching or testing, find

More information

Management of Pharmaceutical Wastes from Healthcare & Households. Rudy Vingris Product Manager PharmEcology Services Waste Management, Inc.

Management of Pharmaceutical Wastes from Healthcare & Households. Rudy Vingris Product Manager PharmEcology Services Waste Management, Inc. Management of Pharmaceutical Wastes from Healthcare & Households Rudy Vingris Product Manager PharmEcology Services Waste Management, Inc. Legal Disclaimer This presentation is solely for educational purposes

More information

Selling/Closing a Medical Practice

Selling/Closing a Medical Practice Selling/Closing a Medical Practice This publication is a snapshot of South Carolina laws, regulations and best practices as of July 2009. The material presented is likely to evolve and change from year

More information

May 2010 Rhonda Dash, MPH Director, Research Compliance

May 2010 Rhonda Dash, MPH Director, Research Compliance May 2010 Rhonda Dash, MPH Director, Research Compliance Introduce the new Director of Research Compliance Review Applicable Federal Regulations Review Applicable State Regulations Review UNTHSC new Policies

More information

What is a hazardous drug? Hazardous Drugs: NIOSH. Pharmaceutical Waste: Hazardous pharmaceutical Waste 衛 福 部 疾 病 管 制 署

What is a hazardous drug? Hazardous Drugs: NIOSH. Pharmaceutical Waste: Hazardous pharmaceutical Waste 衛 福 部 疾 病 管 制 署 殘 餘 藥 物 之 處 置 衛 福 部 疾 病 管 制 署 中 區 傳 染 病 防 治 醫 療 網 王 任 賢 指 揮 官 What is a hazardous drug? ASHP 2004 TAB criteria for considering a drug hazardous (adopted by OSHA): 1. Carcinogenicity 2. Teratogenicity 3.

More information

Re: Proposed Changes to the Medicare Advantage and the Medicare Prescription Drug Benefit Programs for Contract Year 2012 and Other Proposed Changes

Re: Proposed Changes to the Medicare Advantage and the Medicare Prescription Drug Benefit Programs for Contract Year 2012 and Other Proposed Changes January 11, 2011 Submitted via: http://www.cms.hhs.gov/erulemaking Dr. Donald M. Berwick, Administrator Centers for Medicare & Medicaid Services Department of Health and Human Services 200 Independence

More information

NORTH DAKOTA ATTORNEY GENERAL Wayne Stenehjem

NORTH DAKOTA ATTORNEY GENERAL Wayne Stenehjem NORTH DAKOTA ATTORNEY GENERAL Wayne Stenehjem Prescription Drug Take Back Program ND Attorney General Wayne Stenehjem History of Prescription Take-Back In December of 2009, NDAG Stenehjem created the Prescription

More information

NH Laws / Rules Regarding Limited Retail Drug Distributors

NH Laws / Rules Regarding Limited Retail Drug Distributors NH Laws / Rules Regarding Limited Retail Drug Distributors 318:1, VII-a. "Limited retail drug distributor'' means a distributor of legend devices or medical gases delivered directly to the consumer pursuant

More information

Appendix D. Criteria and Procedures for Model Home-Generated Pharmaceutical Waste Collection and Disposal Programs

Appendix D. Criteria and Procedures for Model Home-Generated Pharmaceutical Waste Collection and Disposal Programs Appendix D. Criteria and Procedures for Model Home-Generated Pharmaceutical Waste Collection and Disposal Programs Senate Bill 966 (Simitian, Chapter 542, Statutes of 2007) requires the California Integrated

More information

Pharmaceutical Waste Compliance Program

Pharmaceutical Waste Compliance Program Pharmaceutical Waste Compliance Program Corporate Overview Stericycle Services Medical Waste Management Sharps Disposal Management Product Recalls & Retrieval OSHA Compliance Training Pharmaceutical &

More information

Comprehensive Medical Waste and Unused Medication Management Solutions Provider NASDAQ: SMED

Comprehensive Medical Waste and Unused Medication Management Solutions Provider NASDAQ: SMED Comprehensive Medical Waste and Unused Medication Management Solutions Provider NASDAQ: SMED INVESTOR PRESENTATION NOVEMBER Safe Harbor These slides contain (and the accompanying oral discussion will contain)

More information

SOLID WASTE MANAGEMENT PLAN Peoria County September 3, 2013 Medical Waste Background

SOLID WASTE MANAGEMENT PLAN Peoria County September 3, 2013 Medical Waste Background SOLID WASTE MANAGEMENT PLAN Peoria County September 3, 2013 Medical Waste Background Medical Waste The proper handling and disposal of medical wastes (syringes, medical instruments, vials, pathological

More information

3341-7-09 Use of Controlled Substances in Research.

3341-7-09 Use of Controlled Substances in Research. 3341-7-09 Use of Controlled Substances in Research. Applicability Faculty and staff who hold federal Drug Enforcement Administration (DEA) licenses to use controlled substances for research purposes. Responsible

More information

Narcotic Treatment Programs

Narcotic Treatment Programs This is a copy of two small segments of the DEA Pharmacist Manual, April 2004. This material is absent from the DEA Practitioner s Manual. Narcotic Treatment Programs The Narcotic Addict Treatment Act

More information

NOTE: In the event that the seal is accidentally broken, the narcotic may be wasted via narcotic wastage procedures.

NOTE: In the event that the seal is accidentally broken, the narcotic may be wasted via narcotic wastage procedures. HOSPITAL NAME INSTITUTIONAL POLICY AND PROCEDURE (IPP) Department: Manual: Section: TITLE/DESCRIPTION POLICY NUMBER NARCOTICS AND CONTROLLED DRUGS EFFECTIVE DATE REVIEW DUE REPLACES NUMBER NO. OF PAGES

More information

SHARPS COLLECTION PROGRAM PLAN FOR THE PRINCE EDWARD ISLAND MEDICAL SHARP STEWARDSHIP PROGRAM

SHARPS COLLECTION PROGRAM PLAN FOR THE PRINCE EDWARD ISLAND MEDICAL SHARP STEWARDSHIP PROGRAM SHARPS COLLECTION PROGRAM PLAN FOR THE PRINCE EDWARD ISLAND MEDICAL SHARP STEWARDSHIP PROGRAM DECEMBER 2014 EXECUTIVE SUMMARY On June 10, 2014 Prince Edward Island approved the Environmental Protection

More information

Exceptions to the Rule: A Pharmacy Law Presentation. Objectives DISCLAIMER 10/16/2015

Exceptions to the Rule: A Pharmacy Law Presentation. Objectives DISCLAIMER 10/16/2015 Exceptions to the Rule: A Pharmacy Law Presentation Eric Roath, Pharm.D. Director of Professional Practice Michigan Pharmacists Association Objectives 1. Identify basic legal frameworks that govern the

More information

Health Care Alert. Disposing of Hazardous Pharmaceutical Wastes: It s Not Just for Hospitals Anymore

Health Care Alert. Disposing of Hazardous Pharmaceutical Wastes: It s Not Just for Hospitals Anymore December 2008 Authors: Raymond P. Pepe +1.717.231.5988 raymond.pepe@klgates.com Patricia Shea +1.717.231.5870 patricia.shea@klgates.com Jessica Leigh Wray +1.717.231.4815 leigh.wray@klgates.com K&L Gates

More information

WASHINGTON LAWS, 1987

WASHINGTON LAWS, 1987 ensure compliance with this chapter and the treatment standard authorized by this chapter. A methadone treatment center shall not have a caseload in excess of three hundred fifty persons. The caseload

More information

LEGISLATURE OF THE STATE OF IDAHO Sixty-third Legislature Second Regular Session - 2016 IN THE SENATE SENATE BILL NO. 1322

LEGISLATURE OF THE STATE OF IDAHO Sixty-third Legislature Second Regular Session - 2016 IN THE SENATE SENATE BILL NO. 1322 LEGISLATURE OF THE STATE OF IDAHO Sixty-third Legislature Second Regular Session - IN THE SENATE SENATE BILL NO. BY HEALTH AND WELFARE COMMITTEE 0 0 AN ACT RELATING TO EPINEPHRINE AUTO-INJECTORS; AMENDING

More information

Date Submitted: July 20, 2000 Date Reviewed: May 31, 2005 January 17, 2006 March 17, 2009 Subject: Administration of Medication

Date Submitted: July 20, 2000 Date Reviewed: May 31, 2005 January 17, 2006 March 17, 2009 Subject: Administration of Medication POLICY SOMERSET COUNTY BOARD OF EDUCATION 1. PURPOSE Date Submitted: July 20, 2000 Date Reviewed: May 31, 2005 January 17, 2006 March 17, 2009 Subject: Administration of Medication Number: 600-32 Date

More information

Patient Safety. Road Map to Controlled Substance Diversion Prevention

Patient Safety. Road Map to Controlled Substance Diversion Prevention Patient Safety Road Map to Controlled Substance Diversion Prevention Road Map to Diversion Prevention safe S Safety Teams/ Organizational Structure A Access to information/ Accurate Reporting/ Monitoring/

More information

Schedule 8 and Declared Schedule 4 Medicines Management Policy

Schedule 8 and Declared Schedule 4 Medicines Management Policy Department of Health and Human Services SYSTEM PURCHASING AND PERFORMANCE - MEDICATION STRATEGY AND REFORM Schedule 8 and Declared Schedule 4 Medicines Management Policy SDMS Id Number: Effective From:

More information

Administrative Policy

Administrative Policy Administrative Policy Number: 411 Effective: 4/7/2011 Supersedes: n/a Page: 1 of 8 Subject: Use of Controlled Substances in Research 1.0. PURPOSE: The purpose of this policy is to set forth procedures

More information

BOARD OF PHARMACY DIVISION 41 OPERATION OF PHARMACIES (RETAIL AND INSTITUTIONAL DRUG OUTLETS) CONSULTING PHARMACISTS AND OPERATION OF DRUG ROOMS

BOARD OF PHARMACY DIVISION 41 OPERATION OF PHARMACIES (RETAIL AND INSTITUTIONAL DRUG OUTLETS) CONSULTING PHARMACISTS AND OPERATION OF DRUG ROOMS BOARD OF PHARMACY DIVISION 41 OPERATION OF PHARMACIES (RETAIL AND INSTITUTIONAL DRUG OUTLETS) CONSULTING PHARMACISTS AND OPERATION OF DRUG ROOMS 855-041-6050 Definitions Hospitals with Pharmacies (1) In

More information

UW School of Dentistry Comprehensive Medication Policy

UW School of Dentistry Comprehensive Medication Policy UNIVERSITY OF WASHINGTON SCHOOL OF DENTISTRY Subject: UW School of Dentistry Comprehensive Medication Policy Policy Number: Effective Date: December 2014 Revision Dates: June 2015 PURPOSE This policy provides

More information

Controlled substances Identifying risks and internal audit focus areas

Controlled substances Identifying risks and internal audit focus areas Controlled substances Identifying risks and internal audit focus areas Introduction With a mission focused on improving the health of patients and taking care of the sick, health care providers face unique

More information

Re: Docket No. DEA-218, Electronic Prescriptions for Controlled Substances, Interim Final Rule with Request for Comment

Re: Docket No. DEA-218, Electronic Prescriptions for Controlled Substances, Interim Final Rule with Request for Comment American Society of Health-System Pharmacists 7272 Wisconsin Avenue Bethesda, Maryland 20814 (301) 657-3000 Fax: (301) 664-8877 www.ashp.org Drug Enforcement Administration Attention: DEA Federal Register

More information

SECTION.1800 - PRESCRIPTIONS

SECTION.1800 - PRESCRIPTIONS SECTION.1800 - PRESCRIPTIONS 21 NCAC 46.1801 EXERCISE OF PROFESSIONAL JUDGMENT IN FILLING PRESCRIPTIONS (a) A pharmacist or device and medical equipment dispenser shall have a right to refuse to fill or

More information

ADMINISTRATION OF MEDICATION

ADMINISTRATION OF MEDICATION ADMINISTRATION OF MEDICATION IN SCHOOLS MARYLAND STATE SCHOOL HEALTH SERVICES GUIDELINE JANUARY 2006 (Reference Updated March 2015) Maryland State Department of Education Maryland Department of Health

More information

Hazardous Pharmaceutical Waste Management. Written by: Matthew Teeter, Environmental Compliance Consultant

Hazardous Pharmaceutical Waste Management. Written by: Matthew Teeter, Environmental Compliance Consultant Hazardous Pharmaceutical Waste Management Written by: Matthew Teeter, Environmental Compliance Consultant Identifying Hazardous Pharmaceuticals Certain pharmaceuticals used in hospitals, medical centers

More information

in The Institute of Internal Auditor's

in The Institute of Internal Auditor's Office of Internal Audit January 8, 2014 Dr. Kirk A. Calhoun, M.D. UT Health Northeastt 11937 U. S. Hwy 271 Tyler, TX 75708 Dr. Calhoun: The was completed as part off our Audit Plan. The objective of this

More information

EOC 0002. Quality Through Compliance. Policies and Procedures. HAWAII HEALTH SYSTEMS C O R P O R A T I O N Touching Lives Everyday" N/A

EOC 0002. Quality Through Compliance. Policies and Procedures. HAWAII HEALTH SYSTEMS C O R P O R A T I O N Touching Lives Everyday N/A HAWAII HEALTH SYSTEMS C O R P O R A T I O N Touching Lives Everyday" Policies and Procedures Subject: Corporate Policy on Medical Waste Quality Through Compliance Issued by: Corporate Compliance Committee

More information

Nurse-Managed Medication Inventory

Nurse-Managed Medication Inventory Nurse-Managed Medication Inventory Information for Employers College of Registered Nurses of British Columbia 2855 Arbutus Street Vancouver, BC Canada V6J 3Y8 T: 604.736.7331 F: 604.738.2272 Toll-free:

More information

247 CMR: BOARD OF REGISTRATION IN PHARMACY

247 CMR: BOARD OF REGISTRATION IN PHARMACY 247 CMR 9.00: CODE OF PROFESSIONAL CONDUCT; PROFESSIONAL STANDARDS FOR REGISTERED PHARMACISTS, PHARMACIES AND PHARMACY DEPART- MENTS Section 9.01: Code of Professional Conduct for Registered Pharmacists,

More information

Vanderbilt University Medical Center Pharmaceutical Waste Program USER INSERVICE

Vanderbilt University Medical Center Pharmaceutical Waste Program USER INSERVICE Vanderbilt University Medical Center Pharmaceutical Waste Program USER INSERVICE Training and Education Plan This session is intended to train and provide super-users with necessary resources to effectively

More information

Medical Waste Management Plan

Medical Waste Management Plan Medical Waste Management Plan The Kern County Environmental Health Division is the local agency designated by the California Department of Public Health to implement the Medical Waste Management Act. This

More information

105 CMR: DEPARTMENT OF PUBLIC HEALTH 105 CMR 210.000: THE ADMINISTRATION OF PRESCRIPTION MEDICATIONS IN PUBLIC AND PRIVATE SCHOOLS

105 CMR: DEPARTMENT OF PUBLIC HEALTH 105 CMR 210.000: THE ADMINISTRATION OF PRESCRIPTION MEDICATIONS IN PUBLIC AND PRIVATE SCHOOLS 105 CMR 210.000: THE ADMINISTRATION OF PRESCRIPTION MEDICATIONS IN PUBLIC AND PRIVATE SCHOOLS Section 210.001: Purpose 210.002: Definitions 210.003: Policies Governing the Administration of Prescription

More information

SCOPE OF PRACTICE FOR ARNPS

SCOPE OF PRACTICE FOR ARNPS FLORIDA'S PROHIBITION ON ADVANCED REGISTERED NURSE PRACTITIONERS (ARNPs) PRESCRIBING CONTROLLED SUBSTANCES AND THE REQUIREMENTS TO REPORT SUCH ACTIVITY Florida is one of the two states that does not allow

More information

Electronic Prescribing In New York State

Electronic Prescribing In New York State Electronic Prescribing In New York State Joshua S. Vinciguerra, Director Bureau of Narcotic Enforcement October 28, 2015 October 28, 2015 2 Overview Review the problem & e-prescribing mandate Describe

More information

Planning Issues for Hospital Pharmacies with Growing Outpatient Populations

Planning Issues for Hospital Pharmacies with Growing Outpatient Populations Planning Issues for Hospital Pharmacies with Growing Outpatient Populations In recent years, there has been an increasing emphasis in healthcare on the provision of ambulatory care services. It is predicted

More information

MESSAGE FROM THE ADMINISTRATOR

MESSAGE FROM THE ADMINISTRATOR i ii MESSAGE FROM THE ADMINISTRATOR The Drug Enforcement Administration (DEA) is pleased to provide this guideline to assist in the understanding of the provisions of the Controlled Substances Act of 1970

More information

Re: Docket No. DEA-218, Electronic Prescriptions for Controlled Substances

Re: Docket No. DEA-218, Electronic Prescriptions for Controlled Substances American Society of Health-System Pharmacists 7272 Wisconsin Avenue Bethesda, Maryland 20814 (301) 657-3000 Fax: (301) 664-8877 www.ashp.org Drug Enforcement Administration Attention: DEA Federal Register

More information

Managing Pharmaceutical Wastes: Law and Regulations

Managing Pharmaceutical Wastes: Law and Regulations Managing Pharmaceutical Wastes: Law and Regulations James T. Price Missouri Waste Control Coalition Conference June 30, 2014 2014 WA 5625923.1 From the Missouri Department of Natural Resources Health Care:

More information

Michael D. Bullek BSP Rph. Commissioner, New Hampshire Board of Pharmacy

Michael D. Bullek BSP Rph. Commissioner, New Hampshire Board of Pharmacy Michael D. Bullek BSP Rph. Commissioner, New Hampshire Board of Pharmacy Legislative changes PDMP program changes 503B outsourcing facilities Rules changes Ph800 review Ph300 Ph400 Ph700 Current issues

More information

STANDARD OPERATING PROCEDURE #401 CONTROLLED SUBSTANCES

STANDARD OPERATING PROCEDURE #401 CONTROLLED SUBSTANCES STANDARD OERATING ROCEDURE #401 CONTROLLED SUBSTANCES 1. UROSE This Standard Operating rocedure (SO) describes procedures for acquiring, storing, using and discarding controlled substances. 2. RESONSIBILITY

More information

Texas Regulations on Medical Waste

Texas Regulations on Medical Waste TCEQ REGULATORY GUIDANCE Waste Permits Division RG-001 Revised September 2012 Texas Regulations on Medical Waste This is a regulatory guide to assist generators of medical waste, transporters of untreated

More information

16.19.10.11 PUBLIC HEALTH CLINICS: A. CLINIC LICENSURE: (1) All clinics where dangerous drugs are administered, distributed or dispensed shall obtain

16.19.10.11 PUBLIC HEALTH CLINICS: A. CLINIC LICENSURE: (1) All clinics where dangerous drugs are administered, distributed or dispensed shall obtain 16.19.10.11 PUBLIC HEALTH CLINICS: A. CLINIC LICENSURE: (1) All clinics where dangerous drugs are administered, distributed or dispensed shall obtain a limited drug permit as described in Section 61-11-14

More information

CONNECTICUT. Downloaded January 2011 19 13 D8T. CHRONIC AND CONVALESCENT NURSING HOMES AND REST HOMES WITH NURSING SUPERVISION

CONNECTICUT. Downloaded January 2011 19 13 D8T. CHRONIC AND CONVALESCENT NURSING HOMES AND REST HOMES WITH NURSING SUPERVISION CONNECTICUT Downloaded January 2011 19 13 D8T. CHRONIC AND CONVALESCENT NURSING HOMES AND REST HOMES WITH NURSING SUPERVISION (d) General Conditions. (6) All medications shall be administered only by licensed

More information

Subject: Health; prescription drugs; Vermont Prescription Monitoring 5 System

Subject: Health; prescription drugs; Vermont Prescription Monitoring 5 System 0 Page of S. Introduced by Senator Sears Referred to Committee on Date: Subject: Health; prescription drugs; Vermont Prescription Monitoring System Statement of purpose of bill as introduced: This bill

More information

D R A F T SUMMARY. prescription monitoring information submitted under ORS 431A.860 to

D R A F T SUMMARY. prescription monitoring information submitted under ORS 431A.860 to LC 0 Regular Session // (SCT/ps) D R A F T SUMMARY Requires Oregon Health Authority to disclose prescription monitoring information to practitioner or pharmacist or member of practitioner s or pharmacist

More information

Definitions For the purpose of this policy, the following definitions shall apply:

Definitions For the purpose of this policy, the following definitions shall apply: 5141.21 Administration of Student Medications in the Schools A licensed school nurse, or in the absence of such nurse, qualified personnel for schools may administer medication to students in the school

More information

ADMINISTRATION OF MEDICATIONS POLICY

ADMINISTRATION OF MEDICATIONS POLICY Policy 6.007. ADMINISTRATION OF MEDICATIONS POLICY It is the policy of Cooperative Educational Services (C.E.S.) that students who require any medications to be administered during school hours, including

More information

Inventory Management

Inventory Management Inventory Management Chapter Outline Inventory Management Inventory Systems Computer & Inventory Ordering Forms Stocking & Storing Inventory Management Inventory A listing of medication of the goods or

More information

DEPARTMENT OF JUSTICE. Drug Enforcement Administration. 21 CFR Parts 1305, 1311. [Docket No. DEA-217F] RIN 1117-AA60

DEPARTMENT OF JUSTICE. Drug Enforcement Administration. 21 CFR Parts 1305, 1311. [Docket No. DEA-217F] RIN 1117-AA60 Billing code 4410-09-P DEPARTMENT OF JUSTICE Drug Enforcement Administration 21 CFR Parts 1305, 1311 [Docket No. DEA-217F] RIN 1117-AA60 Electronic Orders for Controlled Substances AGENCY: Drug Enforcement

More information

12 LC 33 4683S. The House Committee on Health and Human Services offers the following substitute to HB 972: A BILL TO BE ENTITLED AN ACT

12 LC 33 4683S. The House Committee on Health and Human Services offers the following substitute to HB 972: A BILL TO BE ENTITLED AN ACT The House Committee on Health and Human Services offers the following substitute to HB 972: A BILL TO BE ENTITLED AN ACT 1 2 3 4 5 6 7 8 9 10 11 12 13 To amend Chapter 34 of Title 43 of the Official Code

More information

Guidance for Industry Bar Code Label Requirements Questions and Answers

Guidance for Industry Bar Code Label Requirements Questions and Answers Guidance for Industry Bar Code Label Requirements Questions and Answers For questions on the content of this guidance, contact the Center for Drug Evaluation and Research or the Center for Biologics Evaluation

More information

PHARMACY SECURITY BEST PRACTICES

PHARMACY SECURITY BEST PRACTICES CHRIS CHRISTIE Governor KIM GUADAGNO Lt. Governor Division of Consumer Affairs Office of the Director 124 Halsey Street, 7 th Floor, Newark NJ PHARMACY SECURITY BEST PRACTICES Published May 1, 2013 New

More information

BUSINESS ASSOCIATE AGREEMENT. Business Associate. Business Associate shall mean.

BUSINESS ASSOCIATE AGREEMENT. Business Associate. Business Associate shall mean. BUSINESS ASSOCIATE AGREEMENT This Business Associate Agreement is made as of the day of, 2010, by and between Methodist Lebonheur Healthcare, on behalf of itself and all of its affiliates ( Covered Entity

More information

The Comprehensive Environmental Response,

The Comprehensive Environmental Response, Purpose and Applicability of Regulations The Comprehensive Environmental Response, Compensation, and Liability Act (CERCLA) was enacted by Congress in 1980 to clean up the nation s hazardous waste sites

More information

RCRA Applied to Retail and Pharmaceutical Wastes, How to Manage a Work in Progress. Gregory W. Blount Troutman Sanders LLP Atlanta, GA

RCRA Applied to Retail and Pharmaceutical Wastes, How to Manage a Work in Progress. Gregory W. Blount Troutman Sanders LLP Atlanta, GA RCRA Applied to Retail and Pharmaceutical Wastes, How to Manage a Work in Progress Gregory W. Blount Troutman Sanders LLP Atlanta, GA TABLE OF CONTENTS INTRODUCTION... 1 A. Determining Whether a Pharmaceutical

More information

VERMONT2007. Drugs and Medical Supply Repository Study. Report to the Legislature on Act 139 Sec. 6 Report Relating to 8 V.S.A. 107 January 15, 2007

VERMONT2007. Drugs and Medical Supply Repository Study. Report to the Legislature on Act 139 Sec. 6 Report Relating to 8 V.S.A. 107 January 15, 2007 VERMONT2007 Drugs and Medical Supply Repository Study Report to the Legislature on Act 139 Sec. 6 Report Relating to 8 V.S.A. 107 108 Cherry Street, PO Box 70 Burlington, VT 05402 1.802.951.1258 healthvermont.gov

More information

Guidance for Industry

Guidance for Industry Guidance for Industry Toll-Free Number Labeling and Related Requirements for Over-the-Counter and Prescription Drugs Marketed With Approved Applications Small Entity Compliance Guide U.S. Department of

More information

Management Solutions

Management Solutions Pharmaceutical Waste Management Solutions Wisconsin H2E April 9 th, 2009 MaryAnn Jensen Account Executive PharmEcology 414-292-3959 mjensen@pharmecology.com Partner With the Leaders! Identification PharmEcology:

More information

NOTICE REQUIREMENTS FOR PRESCRIPTION MONITORING PROGRAMS

NOTICE REQUIREMENTS FOR PRESCRIPTION MONITORING PROGRAMS NOTICE REQUIREMENTS FOR PRESCRIPTION MONITORING PROGRAMS This project was supported by Grant No. G1299ONDCP03A, awarded by the Office of National Drug Control Policy. Points of view or opinions in this

More information

IAC 10/5/11 Pharmacy[657] Ch 40, p.1 CHAPTER 40 TECH-CHECK-TECH PROGRAMS

IAC 10/5/11 Pharmacy[657] Ch 40, p.1 CHAPTER 40 TECH-CHECK-TECH PROGRAMS IAC 10/5/11 Pharmacy[657] Ch 40, p.1 CHAPTER 40 TECH-CHECK-TECH PROGRAMS 657 40.1(155A) Purpose and scope. The board may authorize a hospital pharmacy to participate in a tech-check-tech program. The board

More information

Review of Maine Pharmacy Rules. An update of new rules adopted 12/11/2013

Review of Maine Pharmacy Rules. An update of new rules adopted 12/11/2013 Review of Maine Pharmacy Rules An update of new rules adopted 12/11/2013 This review is meant to highlight important changes and additions to the rules as adopted on 12/11/2013. We will cover the rules

More information

RULE. The Administration of Medication in Louisiana Public Schools

RULE. The Administration of Medication in Louisiana Public Schools RULE The Administration of Medication in Louisiana Public Schools Developed in 1994 by The Louisiana State Board of Elementary and Secondary Education and The Louisiana State Board of Nursing Amendments

More information

DSCSA Updates and Readiness Check: Requirements for Dispensers and other Trading Partners

DSCSA Updates and Readiness Check: Requirements for Dispensers and other Trading Partners DSCSA Updates and Readiness Check: Requirements for Dispensers and other Trading Partners U.S. Food and Drug Administration Center for Drug Evaluation and Research July 2015 Who is a Dispenser? DISPENSER.

More information

CHAPTER 9 RECORDS MANAGEMENT (Revised April 18, 2006)

CHAPTER 9 RECORDS MANAGEMENT (Revised April 18, 2006) CHAPTER 9 RECORDS MANAGEMENT (Revised April 18, 2006) WHAT IS THE PURPOSE OF RECORDS MANAGEMENT? 1. To implement a cost-effective Department-wide program that provides for adequate and proper documentation

More information